Trial Profile
A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of a specific immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of house dust mites of Dermatophagoides pteronyssinus in patients with rhinitis/rhinoconjunctivitis with or without allergic asthma bronchiale [Estudio multicentrico, aleatorizado, controlado con placebo y doble ciego para evaluar la seguridad y la eficacia de una inmunoterapia especifica con una preparacion alergoide de acaros del polvo Dermatophagoides pteronyssinus adsorbida en hidroxido de aluminio en pacientes con rinitis/rinoconjuntivitis con o sin asma bronquial alergica]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic asthma; Allergic rhinitis; Rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Allergopharma
- 12 Apr 2022 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 28 Jun 2011 New trial record